Marimastat oral matrix metalloproteinase inhibitor data

BBIOY reported results of several open label, 28-day Phase II studies and a meta-analysis of the trials. As presented at the Congress of the European Society for Medical Oncology in Vienna, the data

Read the full 334 word article

How to gain access

Continue reading with a
two-week free trial.